Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.64 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.64 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.64 |
| ▸ | CDK1 | P06493 | 1/20 | 0.64 |
| ▸ | CSF1R | P07333 | 1/20 | 0.64 |
| ▸ | PRKACA | P17612 | 1/20 | 0.64 |
| ▸ | FLT1 | P17948 | 1/20 | 0.64 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.64 |
| ▸ | CDK2 | P24941 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | AKT1 | P31749 | 1/20 | 0.64 |
| ▸ | FLT4 | P35916 | 1/20 | 0.64 |
| ▸ | KDR | P35968 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 1/20 | 0.64 |
| ▸ | GSK3A | P49840 | 1/20 | 0.64 |
| ▸ | GSK3B | P49841 | 1/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10763894 | 1.00 | ALDH1A1 (0.71) | ALDH1A1NPC1LMNAROCK2RPS6KA5 | |
| SCHEMBL10761711 | 1.00 | ALDH1A1 (0.71) | ALDH1A1NPC1LMNAROCK2RPS6KA5 | |
| SCHEMBL1101522 | 0.88 | ALDH1A1 (0.77) | ALDH1A1NPC1LMNAROCK2RPS6KA5 | |
| SCHEMBL5968858 | 0.88 | ALDH1A1 (0.77) | ALDH1A1NPC1LMNAROCK2RPS6KA5 | |
| SCHEMBL751213 | 0.88 | ALDH1A1 (0.77) | ALDH1A1NPC1LMNAROCK2RPS6KA5 | |
| SCHEMBL31756926 | 0.85 | ALDH1A1 (0.60) | ALDH1A1NPC1LMNAROCK2RPS6KA5 | |
| SCHEMBL3756762 | 0.85 | ALDH1A1 (0.73) | ALDH1A1NPC1LMNAROCK2RPS6KA5 | |
| SCHEMBL3755011 | 0.85 | ALDH1A1 (0.73) | ALDH1A1NPC1LMNAROCK2RPS6KA5 | |
| SCHEMBL2919150 | 0.85 | ALDH1A1 (0.73) | ALDH1A1NPC1LMNAROCK2RPS6KA5 | |
| SCHEMBL17369057 | 0.85 | ALDH1A1 (0.73) | ALDH1A1NPC1LMNAROCK2RPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0158526-B1 | IMPROVEMENTS IN OR RELATING TO ANTICONVULSANT AGENTS | ELI LILLY AND COMPANY (US) | 1987-07-08 | — | — | EP | claimed |
| EP-0078845-B1 | ANTI-CONVULSANT | CLARK, Charles Randall (US) | 1987-02-04 | — | — | EP | claimed |
| US-4629740-A | ENANTIOMORPHS OF 4-AMINO-N/1-PHENYLETHYL/BENZAMIDE | ELI LILLY AND COMPANY (US) | 1986-12-16 | — | — | US | claimed |
| EP-0158526-A1 | Improvements in or relating to anticonvulsant agents | ELI LILLY AND COMPANY (US) | 1985-10-16 | — | — | EP | claimed |
| EP-0078845-A4 | ANTI-CONVULSANT. | CLARK CHARLES RANDALL | 1983-09-02 | — | — | EP | claimed |
| EP-0078845-A1 | ANTI-CONVULSANT. | CLARK CHARLES RANDALL | 1983-05-18 | — | — | EP | claimed |
| US-4379165-A | Anti-convulsant | RESEARCH CORPORATION (US) | 1983-04-05 | — | — | US | claimed |
| WO-1982004046-A1 | ANTI-CONVULSANT | CLARK CHARLES RANDALL | 1982-11-25 | — | — | WO | claimed |
| US-20090137681-A1 | Sirtuin Inhibiting Compounds | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-05-28 | — | — | US | disclosed |
| WO-2007084162-A2 | SIRTUIN INHIBITING COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-0158526-B1 | IMPROVEMENTS IN OR RELATING TO ANTICONVULSANT AGENTS | ELI LILLY AND COMPANY (US) | 1987-07-08 | — | — | EP | disclosed |
| EP-0078845-B1 | ANTI-CONVULSANT | CLARK, Charles Randall (US) | 1987-02-04 | — | — | EP | disclosed |
| US-4629740-A | ENANTIOMORPHS OF 4-AMINO-N/1-PHENYLETHYL/BENZAMIDE | ELI LILLY AND COMPANY (US) | 1986-12-16 | — | — | US | disclosed |
| EP-0158526-A1 | Improvements in or relating to anticonvulsant agents | ELI LILLY AND COMPANY (US) | 1985-10-16 | — | — | EP | disclosed |
| EP-0078845-A4 | ANTI-CONVULSANT. | CLARK CHARLES RANDALL | 1983-09-02 | — | — | EP | disclosed |
| EP-0078845-A1 | ANTI-CONVULSANT. | CLARK CHARLES RANDALL | 1983-05-18 | — | — | EP | disclosed |
| US-4379165-A | Anti-convulsant | RESEARCH CORPORATION (US) | 1983-04-05 | — | — | US | disclosed |
| WO-1982004046-A1 | ANTI-CONVULSANT | CLARK CHARLES RANDALL | 1982-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137681-A1 | Sirtuin Inhibiting Compounds | SIRT2, SIRT1, SIRT3 | ALDH1A1 3168/4885NPC1 2806/4885LMNA 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.